ADTX: Aditxt, Inc. Stock

by  •  • Comments Off on ADTX: Aditxt, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1.58
Enterprise Value ($M) 14.34
Book Value ($M) 8.29
Book Value / Share 26.26
Price / Book 0.19
NCAV ($M) -21.86
NCAV / Share -69.27
Price / NCAV -0.07

Profitability (mra)
Return on Invested Capital (ROIC) -2.27
Return on Assets (ROA) -1.23
Return on Equity (ROE) -3.52

Liquidity (mrq)
Quick Ratio 0.08
Current Ratio 0.09

Balance Sheet (mrq) ($M)
Current Assets 2.00
Assets 32.14
Liabilities 23.86
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.13
Operating Income -27.86
Net Income -34.45

Cash Flow Statement (mra) ($M)
Cash From Operations -16.76
Cash from Investing -5.00
Cash from Financing 22.50

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-31 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION
2024-11-18 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-19 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-20 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-04-16 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-03 61,851 164,046 37.70
2025-04-02 82,692 182,272 45.37
2025-04-01 42,947 135,602 31.67
2025-03-31 57,869 188,473 30.70

(click for more detail)

Similar Companies
ACHV – Achieve Life Sciences, Inc. ACXP – Acurx Pharmaceuticals, Inc.
ADIL – Adial Pharmaceuticals, Inc. ADVM – Adverum Biotechnologies, Inc.
AGEN – Agenus Inc.


Financial data and stock pages provided by
Fintel.io